However, it should be noted that we were unable to assess the possibility that SARS-CoV-2–specific CD8+ T cells preferentially trafficked to the site of infection in patients with severe COVID-19, a phenomenon that could provide some degree of localized immune protection (27). The gene discussed is CD8A; the disease is COVID-19.